The global cell culture market was valued at US$ 10.5 Bn in 2020 and is estimated to expand at a CAGR of 9% from 2021 to 2031. The global cell culture market is expected to reach the value of US$ 27.6 Bn by the end of 2031.
Leading-edge Cell Culture Products in Demand for Treatment of Chronic Diseases
Advancements in the cell culture market, in terms of innovations in instruments, media, reagents, and sera are benefitting stakeholders in academic institutes, research centers, biotech companies, and pharmaceutical organizations. Launch of advanced cell culture products and demand for novel therapeutics such as biosimilar are expected to boost the growth of the global cell culture market throughout the assessment tenure.
Get Sample Copy of the Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=405
Since cell culture is primarily associated with the diagnosis of infections, testing of new drugs, and other R&D activities, the market is projected to expand at a robust CAGR during the forecast period. The high prevalence of chronic diseases such as cancer, diabetes, renal diseases, and cardiovascular diseases is fueling the demand for cell culture activities to increase the availability of treatment options and therapeutic agents.
R&D Investments in Immune-boosting Medicines Hold Potentials for Minimizing COVID-19 Risks
The emergence of a new COVID-19 wave in India, China, and the U.K. has brought vaccine companies, biotech companies, and healthcare companies under great scrutiny. In order to win the faith of common individuals and high-risk patients with existing comorbidities, companies in the cell culture market should invest in R&D to innovate and introduce life-saving therapeutics in the market.
Get Report Methodology @ https://www.transparencymarketresearch.com/sample/sample.php?flag=RRM&rep_id=405
Healthcare companies are making use of government stimulus packages and financial schemes provided by the BFSI sector to support research activities in vaccine development and immune-boosting medicines. They should maintain robust supply chains for instruments, sera, media, and reagents to support research activities in academic institutes and biotech companies.
Can Alternatives to Fetal Bovine Serum Transform Cell Culture Market?
Fetal bovine serum (FBS) is commonly used as a serum-supplement for the in vitro cell culture of eukaryotic cells. However, ethical issues pertaining to FBS is affecting research activities in the cell culture market, since fetal bovine serum is derived from the blood drawn from a bovine fetus via a closed system of collection at the slaughterhouse. Hence, researchers are now resorting to alternatives for FBS such as human AB serum and thrombin-activated platelet-rich plasma to excel in cell culture activities.
Alternatives to FBS are becoming necessary, as, in the past years, advanced therapy medicinal products (ATMP) and cell therapy have become increasingly important in terms of clinical use.
Burgeoning Demand for Biosimilars and Biologic Therapeutics Fueling Market Growth
The high demand for biosimilars and other biologic therapeutics is acting as a key driver for the cell culture market. This is evident since cell culture helps to increase efficiency & productivity and reduce the cost of manufacture for biologic therapeutics. Healthcare companies are investing in clinical trials to increase the availability of approved biosimilar products. Such advancements are playing an instrumental role in the development of treatment alternatives for chronic diseases in developed as well as developing countries.
Biotech companies are catering to the increase in demand for efficient and cost-effective biosimilars and biologic therapeutics.
Africa and Middle East Offer Lucrative Growth Opportunities to Companies
Apart from Asia Pacific, companies in the cell culture market are witnessing an increase in the per capita income of individuals in countries of Africa and the Middle East. This improvement in the per capita income can be attributed to rising employment and business opportunities for citizens within the country, and also in countries outside of Africa and the Middle East. Thus, investments toward the development of the healthcare infrastructure in Africa and the Middle East are benefitting stakeholders in the market for cell culture.
Get Custom Research Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=405
In many instances, it has been observed that despite having the income for medical treatments, lack of basic healthcare facilities in rural and remote areas of Africa and the Middle East is affecting patient outcomes. In order to improve patient quality of life, companies should set up biotech companies, research institutes, and academic centers in these regions. These developments are necessary due to high prevalence of rare diseases among the people of Africa and the Middle East.
Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. The firm scrutinizes factors shaping the dynamics of demand in various markets. The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analysed, which will determine growth in the markets over the next decade.
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
USA – Canada Toll Free: 866-552-3453